Prolactinomas

被引：65

作者：

Glezer, Andrea ^{[1
]}

Bronstein, Marcello D. ^{[1
]}

机构：

[1] Univ Sao Paulo, Hosp Clin, Sch Med, Div Endocrinol & Metab,Neuroendocrine Unit,Lab Ce, BR-05403000 Sao Paulo, Brazil

来源：

ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA | 2015年 / 44卷 / 01期

关键词：

Hyperprolactinemia; Prolactinoma; Pituitary tumors; Hypogonadotropic hypogonadism; Infertility; Prolactin; Dopaminergic agonists; LONG-TERM BROMOCRIPTINE; CABERGOLINE TREATMENT; INCREASED PREVALENCE; DOPAMINE AGONISTS; HYPERPROLACTINEMIA; RESISTANT; RECEPTOR; MANAGEMENT; DIAGNOSIS; RECOVERY;

D O I：

10.1016/j.ecl.2014.11.003

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Identifying the correct cause of hyperprolactinemia is crucial for treatment. Prolactinoma is the most common pathologic cause of hyperprolactinemia. Dopamine agonists are efficacious in about 80% to 90% of patients with prolactinoma, leading to reduction of serum prolactin levels and tumor dimensions. Neurosurgery, mainly by the transsphenoidal route, is indicated in cases of intolerant and resistant dopamine agonists. Radiotherapy is rarely used because of its side effects and low efficacy. The alkylating agent temozolomide showed efficacy for treatment of aggressive and resistant prolactinomas. Other approaches, such as thyrosine kinase inhibitors, are currently being tested and could be an additional tool for these troublesome tumors.

引用

页码：71 / +

页数：9

共 45 条

[1]

[Anonymous], PITUITARY TUMORS PRE

[2] Serum prolactin concentration at presentation of non-functioning pituitary macroadenomas [J].